➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Mallinckrodt
McKinsey
Johnson and Johnson
Colorcon

Last Updated: August 1, 2021

DrugPatentWatch Database Preview

Details for Patent: 9,283,197


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,283,197 protect, and when does it expire?

Patent 9,283,197 protects EPINEPHRINE and is included in one NDA.

Summary for Patent: 9,283,197
Title:More potent and less toxic formulations of epinephrine and methods of medical use
Abstract: The present invention provides pharmaceutical formulations of levorotatory-epinephrine, l-epinephrine, more potent and less toxic than existing pharmaceutical formulations of epinephrine, along with methods of producing and using these pharmaceutical formulations of l-epinephrine.
Inventor(s): Taneja; Jugal K. (Tampa, FL)
Assignee:
Application Number:14/460,845
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,283,197
Patent Claim Types:
see list of patent claims
Formulation; Compound;

Drugs Protected by US Patent 9,283,197

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Belcher EPINEPHRINE epinephrine SOLUTION;INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS 205029-001 Jul 29, 2014 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y EMERGENCY TREATMENT OF ALLERGIC REACTIONS (TYPE I), INCLUDING ANAPHYLAXIS ⤷  Try it Free
Belcher EPINEPHRINE epinephrine SOLUTION;INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS 205029-001 Jul 29, 2014 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y INCREASING MEAN ARTERIAL BLOOD PRESSURE IN ADULT PATIENTS WITH HYPOTENSION ASSOCIATED WITH SEPTIC SHOCK ⤷  Try it Free
Belcher EPINEPHRINE epinephrine SOLUTION;INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS 205029-001 Jul 29, 2014 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y INDUCTION AND MAINTENANCE OF MYDRIASIS DURING INTRAOCULAR SURGERY ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
McKesson
Baxter
McKinsey
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.